SOURCE: Seegene

December 17, 2008 16:39 ET

Seegene Awarded Patent for Haplotyping Using Multiplex PCR

Haplotyping Genetic Screening Technique Promises to Accelerate Detection of Unique Personal Traits for Disease Risk and Drug Response

ROCKVILLE, MD--(Marketwire - December 17, 2008) - Seegene, Inc., a leader in multi-pathogen diagnostic testing, today announced that it has been awarded international patent protection for a break-through technology able to accelerate the detection of highly personal variations in genetic sequences. These genetic variations can identify an individual's risks for a broad range of disorders, such as Alzheimer's disease and coronary artery diseases, or genetic mutations known to cause various cancers.

The patent (WO/2008/143367) issued by the World Intellectual Property Organization covers a novel method for ApoE haplotyping using multiplex PCR. Seegene's proprietary Dual Priming Oligonucleotide (DPO™) technology is being applied to haplotyping -- the investigation of the genetic background and phenotype structures of complex diseases.

According to Jong-Yoon Chun, Founder and Chief Executive Officer, Seegene, "This novel approach to haplotyping using the Seegene multiplex platform allows biomedical researchers to cross a barrier that to this point has frustrated many -- the exploration of observed patterns of genetic sequences that help us understand how the diverse traits reveal themselves as true risks for individuals."

Haplotyping with Seegene's unique DPO technology puts in place a sound foundation for solid scientific advances, Dr. Chun noted, providing a capability to meet pent-up demand for large-scale genetic studies involving thousands of samples.

"Seegene's DPO technology applied to haplotyping is robust yet easy to perform," Dr. Chun added, "providing reliable results with fast turn-around time at a reasonable cost."

Haplotyping emerged as one of the most important fields in the post genomic era due to its potential for identifying the single nucleotide polymorphisms (SNPs) of an individual and quantifying individual susceptibility to targeted traits such as drug responsiveness or diseases while showing stronger correlations than with other genotyping techniques.

Researchers have experimented with a number of advanced methods to determine haplotypes of genes, such as polymerase chain reaction-fragment length polymorphism (PCR-RFLP), allele specific oligonucleotide (ASO) probe, single-strand conformation polymorphism (SSCP), primer extension, oligonucleotide ligation assay (OLA), heteroduplex analysis, and using the multiplex amplification refractory mutation system (ARMS).

These methods to determine haplotypes of genes have proved to be too costly and too complicated for practical research applications, as well as impossible to facilitate high-throughput testing.

By contrast, the novel haplotyping process developed by Seegene applies the unique primer design technology of its proprietary DPO platform to the multiplex PCR technique widely used in molecular genetic analysis. The method allows the genotyping of six different combinations of Apolipoprotein allele types known to be associated with the risk of developing diseases in a single multiplex PCR.

Seegene's DPO technology can be broadly applied to most any genetic test. In addition to DPO's application to ApoE haplotyping, DPO has successfully been applied to various SNPs and somatic single nucleotide mutations detection, including simultaneous two SNP sites genotyping of MTHFR gene for hyperhomocysteimemia, BRAF gene for thyroid cancer, CYP2C19 for drug metabolism, Lamivudine resistant HBV, and JAK2/FLT3 for leukemia. Currently, Seegene is actively seeking targets to apply DPO technology for the performance of detailed genetic analysis.

About Seegene

Seegene, Inc. is a biotechnology company specialized in molecular diagnostics and research applications. It holds a novel detection platform named "Seeplex®," which sets a standard in high-throughput and simultaneous multi-pathogen detection called "multiplexing" in the molecular diagnostics market. Seeplex® technology accurately detects multi-pathogens with high-throughput speed, ultimately providing the most economical basis for saving time, labor and cost. Seegene develops, manufactures and markets innovative molecular diagnostic products and services to a worldwide community. The company has more than 47 distributors in 28 countries, including 2 subsidiary offices in the US and India. Its mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology, and chromosomal analyses using innovative proprietary technologies. For more information please visit www.seegene.com or call +301-762-9066.

Contact Information

  • Contacts:
    Sang-Kil Lee, Ph.D.
    Seegene Inc.
    301-762-9066
    Email Contact
    or
    Constantine Theodoropulos
    Boston Communications
    617-292-7319
    Email Contact